NASDAQ:ACUR - Nasdaq -
0.62
-0.16 (-20.51%)
The current stock price of ACUR is 0.62 null. In the past month the price increased by 6.9%. In the past year, price decreased by -70.19%.
Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers.
Acura Pharmaceuticals
616 N. NORTH COURT SUITE 120
PALATINE IL 60067
CEO: Robert B. Jones
Phone: 847-705-7709
The current stock price of ACUR is 0.62 null. The price decreased by -20.51% in the last trading session.
The exchange symbol of Acura Pharmaceuticals is ACUR and it is listed on the Nasdaq exchange.
ACUR stock is listed on the Nasdaq exchange.
Acura Pharmaceuticals (ACUR) has a market capitalization of 7.37M null. This makes ACUR a Nano Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACUR does not pay a dividend.
Acura Pharmaceuticals (ACUR) will report earnings on 2022-05-16.
Acura Pharmaceuticals (ACUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
The outstanding short interest for Acura Pharmaceuticals (ACUR) is 0.07% of its float. Check the ownership tab for more information on the ACUR short interest.
ChartMill assigns a technical rating of 2 / 10 to ACUR. When comparing the yearly performance of all stocks, ACUR is a bad performer in the overall market: 95.27% of all stocks are doing better.
Over the last trailing twelve months ACUR reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 25.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 100.07% | ||
ROA | -41.13% | ||
ROE | -356.34% | ||
Debt/Equity | 2.52 |